infliximab, Remicade (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

Decreased white and red blood cell and decreased platelet counts have been reported with infliximab. Vasculitis (inflammation of the arteries) also has been reported.

Patients with Crohn's disease or rheumatoid arthritis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of malignant lymphoma. More malignancies have been observed in open-label, uncontrolled clinical studies at a rate several-fold higher than expected in the general population. In controlled studies of TNF-alpha blocking agents, including infliximab, more cases of lymphoma and other malignancies have been observed among patients receiving the agents than among control group patients.

GENERIC AVAILABLE: No

PRESCRIPTION: Yes

PREPARATIONS: Powder for intravenous injection, 100 mg

STORAGE: Infliximab should be refrigerated at 2 C - 8 C (36 F - 46 F)

PRESCRIBED FOR: Infliximab is approved for use alone or combined with methotrexate (Rheumatrex, Trexall) for treating moderate to severe rheumatoid arthritis.

Infliximab is used for reducing the signs and symptoms of inflammation in moderate to severe Crohn's disease and Crohn's disease in which there are fistulas (passageways created when the inflammation penetrates beyond the wall of the intestine).

It also is approved for the treatment of active psoriatic arthritis. Infliximab is helpful in reducing the joint inflammation of juvenile rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis.

It also has been found to be helpful in treating the inflammation of uveitis and sarcoidosis that is not responding to traditional therapies.

Infliximab is approved for use in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.

DOSING: Infliximab is administered intravenously. The recommended dose is a 5 mg/kg infusion at 0, 2, and 6 weeks and then 5 mg/kg every 8 weeks for moderate to severe active Crohn's disease or fistulizing Crohn's disease in adult or pediatric patients. Adults who initially responded then lost response may be treated with 10 mg/kg.

The recommended dose for the treatment of moderately to severely active rheumatoid arthritis is 3 mg/kg at 0, 2, and 6 weeks followed by 3 mg/kg every 8 weeks. Infliximab should be combined with methotrexate. If response is incomplete, up to 10 mg/kg or treating every 4 weeks may be tried.

Medically Reviewed by a Doctor on 1/29/2015


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index